- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04757779
A Single-arm, Phase Ⅱ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung Cancer
14. februar 2021 opdateret af: First People's Hospital of Hangzhou
Anlotinib hydrochloride is a multi-target antiangiogenic drug.
It was recommended by Chinese Society of Clinical Oncology(CSCO) guideline as a third-line treatment for advanced small-cell lung cancer.
This study intends to assess the efficacy and safety of anlotinib hydrochloride combined with irinotecan or docetaxel for second line treatment of nonsensitive relapsed small-cell lung cancer.
Studieoversigt
Status
Rekruttering
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Forventet)
40
Fase
- Fase 2
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Bing Xia, MD
- Telefonnummer: 86 571 56006388
- E-mail: bxia_hzch@hotmail.com
Studiesteder
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kina, 310002
- Rekruttering
- Affiliated Hangzhou Cancer Hospital, Zhejiang University School of Medicine
-
Kontakt:
- Bing Xia, MD
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 75 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- The subject volunteered to participate in the study with informed consent signed.
- Histologically or pathologically confirmed small-cell lung cancer (whether limited or advanced stage).
- Have received at least first-line platinum-based chemotherapy for small-cell lung cancer and comfirmed disease relapse with imaging material. Disease progression during previous chemotherapy or less than 6 month after last chemotherapy.
- Relapsed advanced small-cell lung cancer patients with symptom-controlled brain metastasis or leptomeningeal metastasis (subjects with symptomatic brain metastasis are allowed to receive radiotherapy, whether brain lesions can be deemed as target lesions is decided by investigators.); or patients with newly- discovered brain metastasis or leptomeningeal metastasis diagnosed by CT/MRI. Symptomatic or asymptomatic serosal cavity effusion (pleural effusion, ascites, pericardial effusion, local therapy is allowed). Radiotherapy for symptomatic bone metastasis or elsewhere is allowed as long as response evaluation is not affected.
- Age:18-75 years old.
- Eastern Cooperative Oncology Group (ECOG) performance status(PS) score ≤ 2.
- Survival is expected to be ≥ 6 months.
- At least one non-irradiated target lesion confirmed by CT/MRI scan less than 28 days before first dose of the study drug.
- Male and women must use contraception within first dose to 24 weeks after last dose.
- Major organ functions meet the following criteria within 7 days prior to treatment: blood routine examination and coagulation function (no blood transfusion within 14 days): hemoglobin≥90g/L; Absolute Neutrophil Count(ANC)≥1.5×109/L; Platelet (PLT)≥80×109/L; International normalized ratio(INR)≤1.5,Activated partial thromboplastin time(APTT)≤1.5 × upper limit of normal value(ULN); biochemical test standards: Total bilirubin(TBIL)≤1.5× ULN; ALT/AST≤2.5×ULN without liver metastasis, ALT/AST≤5×ULN with liver metastasis; Creatinine ≤1.25× ULN or endogenous creatinine clearance rate(Ccr)>45ml/min.
Exclusion Criteria:
- Non-small-cell lung cancer (including a mixture of small-cell and non-small cell lung cancer).
- Patients with small-cell lung cancer who relapsed more than 6 months after first- line treatment.
- Medical imaging shows that the distance between the tumor and large vessels is less than 5mm; or lesions invade major blood vessels; or patients who are at risk of severe bleeding during the following treatment which is determined by investigators.
- Medical imaging shows significant pulmonary cavity or necrotic tumor.
- Uncontrolled hypertension (systolic blood pressure≥140mmHg or diastolic blood pressure≥90mmHg, even with optimal medication treatment).
- Subjects with ≥grade Ⅱmyocardial ischemia or myocardial infarction, uncontrolled arrhythmia (include QT interval≥450ms for males, ≥470ms for females).
- Heart function of NYHA grade Ⅲ-Ⅳ or left ventricle ejection fraction(LVEF)<50% confirmed by echocardiography.
- Coagulant function abnormality (INR>1.5 or PT>ULN+4 seconds or APTT> 1.5ULN), with a bleeding tendency or patients is receiving thrombolytic or anticoagulant therapy.
- For subjects who are using an anticoagulant or vitamin K antagonist (e.g. warfarin or heparin or other similar drugs), low dose heparin (6000-12000U daily for an adult) or aspirin (≤100mg daily) is allowed for preventive purposes when INR≤1.5.
- Symptoms or propensity to bleed within 3 months prior to screening (include gastrointestinal hemorrhage, ulcerative gastric bleeding, fecal occult blood 2+ or above, vasculitis).
- Arterial/venous thrombosis within 12 months prior to screening, e.g. cerebrovascular accident (include temporary ischemic attack, cerebral hemorrhage, cerebral infarction), deep venous thrombosis, pulmonary embolism.
- Inherited or acquired bleeding and thrombus propensity (hemophilia, coagulation dysfunction, thrombocytopenia and hypersplenism).
- Unhealed wound or fracture for a long time.
- Major surgical operation or severe traumatic injury, bone fracture or ulcer within 4 weeks prior to screening, which affect drug absorption e.g. inability to swallow, chronic diarrhea and intestinal obstruction.
- Abdominal fistula, gastrointestinal perforation, intraperitoneal abscess within 6 months prior to screening; routine urine test indicate urine protein≥++ or 24- hours proteinuria≥1.0g.
- History of psychotropic drug abuse and cannot abstain from it or with mental disorders.
- Participation in other clinical trials of anti-tumor drugs within 4 weeks prior to screening.
- Previous or concurrent with other types of uncured malignancies, with the exception of cured basal cell carcinoma of the skin, carcinoma in situ of cervix and superficial bladder cancer.
- Pregnant or lactating women, fertile patients who are unwilling or unable to use effective contraceptives.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: anlotinib hydrochloride combined with irinotecan or docetaxel
From the start of the study, the subjects are orally administered with anlotinib 12mg on empty stomach.
Subjects need to take anlotinib 2 weeks continuously and stop for 1 week(every 3 weeks is a cycle).
On Day1 and Day8, subjects are required to inject irinotecan(65mg/m2) or docetaxel(60mg/m2) of a cycle,until disease progression or intolerable toxicity, for 4 cycles at most.
|
From the start of the study, the subjects are orally administered with anlotinib 12mg on empty stomach.Subjects need to take anlotinib 2 weeks continuously and stop for 1 week(every 3 weeks is a cycle),the dose of anlotinib can be adjusted as 12mg,10mg or 8mg according to adverse effects.On Day1 and Day8, subjects are required to inject irinotecan (65mg/m2)or docetaxel (60mg/m2) of a cycle,until disease progression or intolerable toxicity, for 4 cycles at most.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
objective response rate(ORR)
Tidsramme: 2 years
|
the proportion of patients assessed with complete response and partial response
|
2 years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
progression-free survival time(PFS)
Tidsramme: 2 years
|
the time from date of randomization to disease progression or death
|
2 years
|
disease control rate(DCR)
Tidsramme: 2 years
|
the proportion of patients assessed with complete response,partial response and stable disease
|
2 years
|
overall survival(OS)
Tidsramme: 2 years
|
the time from date of randomization to death from any cause
|
2 years
|
quality of life(QoF)assessed by EORTC QLQ-C30
Tidsramme: 2 years
|
Quality of Life assessed by The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire core 30(EORTC QLQ-C30)
|
2 years
|
quality of life(QoF)assessed by EORTC QLQ LC-13
Tidsramme: 2 years
|
Quality of Life assessed by The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer (EORTC QLQ LC-13)
|
2 years
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
30. december 2019
Primær færdiggørelse (Forventet)
30. december 2022
Studieafslutning (Forventet)
30. december 2024
Datoer for studieregistrering
Først indsendt
14. februar 2021
Først indsendt, der opfyldte QC-kriterier
14. februar 2021
Først opslået (Faktiske)
17. februar 2021
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
17. februar 2021
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
14. februar 2021
Sidst verificeret
1. februar 2021
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Luftvejssygdomme
- Neoplasmer
- Lungesygdomme
- Neoplasmer efter sted
- Neoplasmer i luftvejene
- Thoracale neoplasmer
- Karcinom, bronkogent
- Bronkiale neoplasmer
- Lungeneoplasmer
- Småcellet lungekarcinom
- Molekylære mekanismer for farmakologisk virkning
- Enzymhæmmere
- Antineoplastiske midler
- Tubulin modulatorer
- Antimitotiske midler
- Mitose modulatorer
- Topoisomerasehæmmere
- Topoisomerase I-hæmmere
- Docetaxel
- Irinotecan
Andre undersøgelses-id-numre
- HZCH-2019-004
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Ingen
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
produkt fremstillet i og eksporteret fra U.S.A.
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Tilbagefaldende småcellet lungekræft
-
AHS Cancer Control AlbertaCross Cancer InstituteAfsluttetOmfattende Stage Small Cel Lung CancerCanada
-
AstraZenecaAfsluttetRefraktære faste tumorer | Relapsed Small Cell Lung Cancer (SCLC)Forenede Stater, Canada
Kliniske forsøg med anlotinib hydrochloride combined with irinotecan or docetaxel
-
Fudan UniversityIkke rekrutterer endnuSmåcellet lungekræft tilbagevendendeKina
-
Tongji HospitalChia Tai Tianqing Pharmaceutical Group Co., Ltd.Ukendt
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)AfsluttetMavekræft | SpiserørskræftForenede Stater, Canada
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)AfsluttetLungekræftForenede Stater, Canada
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI)AfsluttetHoved- og halskræftForenede Stater
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)AfsluttetBrystkræftForenede Stater
-
Yale UniversityNational Cancer Institute (NCI)AfsluttetUspecificeret fast tumor hos voksne, protokolspecifikForenede Stater
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Rekruttering
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)Afsluttet
-
Sichuan Cancer Hospital and Research InstituteChia Tai Tianqing Pharmaceutical Group Co., Ltd.UkendtLungekræft | Metastatisk lungekræftKina